142 related articles for article (PubMed ID: 37400887)
21. Efficacy of taxane regimens in patients with metastatic angiosarcoma.
Hirata T; Yonemori K; Ando M; Hirakawa A; Tsuda H; Hasegawa T; Chuman H; Namikawa K; Yamazaki N; Fujiwara Y
Eur J Dermatol; 2011; 21(4):539-45. PubMed ID: 21697045
[TBL] [Abstract][Full Text] [Related]
22. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
23. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Ley J; Wildes TM; Daly K; Oppelt P; Adkins D
Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561
[TBL] [Abstract][Full Text] [Related]
24. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.
Izquierdo MA; García M; Pontón JL; Martínez M; Valentí V; Navarro M; Gil M; Cardenal F; Mesía R; Pérez X; Salazar R; Germà-Lluch JR
Eur J Cancer; 2006 Aug; 42(12):1789-96. PubMed ID: 16750622
[TBL] [Abstract][Full Text] [Related]
25. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
26. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
27. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
28. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients.
Nagano T; Yamada Y; Ikeda T; Kanki H; Kamo T; Nishigori C
Cancer; 2007 Aug; 110(3):648-51. PubMed ID: 17582627
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
32. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
33. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
[TBL] [Abstract][Full Text] [Related]
34. Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience.
Fujisawa Y; Nakamura Y; Kawachi Y; Otsuka F
J Dermatolog Treat; 2014 Oct; 25(5):419-23. PubMed ID: 23210914
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
36. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Yasufuku T; Shigemura K; Matsumoto O; Arakawa S; Fujisawa M
J Infect Chemother; 2010 Jun; 16(3):200-5. PubMed ID: 20221782
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
39. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
Ohsumi S; Shimozuma K; Ohashi Y; Takeuchi A; Suemasu K; Kuranami M; Ohno S; Watanabe T
Oncology; 2012; 82(3):131-8. PubMed ID: 22433221
[TBL] [Abstract][Full Text] [Related]
40. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
